Screener
Allogene Therapeutics ALLO Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Amortized Cost | Unrealized Gains | Unrealized Losses | Fair Value |
|---|---|---|---|---|
| Corporate bonds | 69,145 | 10 | (55) | 69,100 |
| U.S. treasury securities | 61,791 | 52 | (9) | 61,834 |
| U.S. agency securities | 18,909 | 2 | (7) | 18,904 |
| Total cash equivalents and investments | $261,815 | $66 | $(249) | $261,632 |
| Classified as: | ||||
| Cash equivalents | $25,055 | |||
| Short-term investments | 236,577 | |||
| Long-term investments | — |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's unrealized gains on investments?
- Allogene Therapeutics (ALLO) reported unrealized gains on investments of $66K in Q1 2026.
- How has Allogene Therapeutics's unrealized gains on investments changed year-over-year?
- Allogene Therapeutics's unrealized gains on investments decreased by 53.2% year-over-year, from $141K to $66K.
- What is the long-term trend for Allogene Therapeutics's unrealized gains on investments?
- Over 5 years (2020 to 2025), Allogene Therapeutics's unrealized gains on investments has grown at a -18.2% compound annual growth rate (CAGR), from $764K to $279K.
Ask your AI about Allogene Therapeutics's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude